NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis $0.58 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.58 +0.00 (+0.16%) As of 05/22/2026 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Galmed Pharmaceuticals Stock (NASDAQ:GLMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Galmed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.58▼$0.6050-Day Range$0.48▼$0.7952-Week Range$0.41▼$2.34Volume15,980 shsAverage Volume137,228 shsMarket Capitalization$3.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials. In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders. The company leverages strategic partnerships for manufacturing and formulation development while pursuing regulatory approvals in key markets. Its clinical trial activities span North America and Europe, with trial sites designed to support potential future commercialization in regions where NASH represents a substantial unmet medical need. Founded in 2001 and headquartered in Tel Aviv, Israel, Galmed maintains corporate offices in the United States to facilitate interactions with regulatory agencies, clinical investigators and potential commercial partners. The company’s leadership team combines expertise in pharmaceutical development, hepatology and global commercialization strategy. Galmed Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol GLMD and remains committed to advancing therapies for patients suffering from progressive liver disease.AI Generated. May Contain Errors. Read More Galmed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreGLMD MarketRank™: Galmed Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGalmed Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGalmed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Galmed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.56% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently decreased by 77.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentGalmed Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Galmed Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Galmed Pharmaceuticals' insider trading history. Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLMD Stock News HeadlinesGalmed Pharmaceuticals (NASDAQ:GLMD) Shares Pass Above Fifty Day Moving Average - Time to Sell?May 21, 2026 | americanbankingnews.comGalmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mgMay 14, 2026 | prnewswire.comMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant. | Behind the Markets (Ad)Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based TherapeuticsMay 6, 2026 | prnewswire.comGalmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersApril 14, 2026 | prnewswire.comGLMD stock shot up 85% pre-market after rising 27% in 5 days – what’s the latest on its Parkinson’s disease therapy?April 9, 2026 | msn.comGalmed Stock Soars On Brain-Penetrating Aramchol FormulationApril 9, 2026 | benzinga.comGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholApril 9, 2026 | prnewswire.comSee More Headlines GLMD Stock Analysis - Frequently Asked Questions How have GLMD shares performed this year? Galmed Pharmaceuticals' stock was trading at $0.7505 at the beginning of the year. Since then, GLMD shares have decreased by 22.7% and is now trading at $0.5801. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its quarterly earnings data on Thursday, May, 22nd. The biopharmaceutical company reported ($0.62) EPS for the quarter. When did Galmed Pharmaceuticals' stock split? Shares of Galmed Pharmaceuticals reverse split on Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Galmed Pharmaceuticals IPO? Galmed Pharmaceuticals (GLMD) raised $37 million in an initial public offering on Thursday, March 13th 2014. The company issued 2,837,400 shares at $12.00-$14.00 per share. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/22/2025Today5/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GLMD's financial health is in the Red zone, according to TradeSmith. GLMD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLMD CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees20Year Founded2000Profitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-29.43% Return on Assets-26.00% Debt Debt-to-Equity RatioN/A Current Ratio6.55 Quick Ratio6.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book0.20Miscellaneous Outstanding Shares5,480,000Free Float4,394,000Market Cap$3.18 million OptionableNot Optionable Beta0.62 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:GLMD) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLMD Stock Alerts